Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
STVN 
Stevanato Group SpA (STVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: STVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $28.63
1 Year Target Price $28.63
| 6 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.8% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.21B USD | Price to earnings Ratio 46.35 | 1Y Target Price 28.63 |
Price to earnings Ratio 46.35 | 1Y Target Price 28.63 | ||
Volume (30-day avg) 11 | Beta 0.55 | 52 Weeks Range 17.07 - 28.00 | Updated Date 09/15/2025 |
52 Weeks Range 17.07 - 28.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) 0.20% | Basic EPS (TTM) 0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.75% | Operating Margin (TTM) 15.03% |
Management Effectiveness
Return on Assets (TTM) 5.2% | Return on Equity (TTM) 9.89% |
Valuation
Trailing PE 46.35 | Forward PE 33.33 | Enterprise Value 7578832321 | Price to Sales(TTM) 6.3 |
Enterprise Value 7578832321 | Price to Sales(TTM) 6.3 | ||
Enterprise Value to Revenue 5.64 | Enterprise Value to EBITDA 32.48 | Shares Outstanding 49691400 | Shares Floating 48894417 |
Shares Outstanding 49691400 | Shares Floating 48894417 | ||
Percent Insiders 1.66 | Percent Institutions 111.55 |
Upturn AI SWOT
Stevanato Group SpA
Company Overview
History and Background
Stevanato Group SpA was founded in 1949 in Italy. Initially focused on glass tubing production, it expanded into pharmaceutical packaging and drug delivery systems. Over the years, it has grown through innovation and acquisitions, becoming a global leader in its field.
Core Business Areas
- Pharmaceutical Systems: Manufactures glass vials, syringes, ampoules, and cartridges for pharmaceutical and biopharmaceutical companies.
- Engineering: Designs and manufactures equipment for processing pharmaceutical glass tubing and forming containers. Includes inspection systems and packaging lines.
- Analytical Services: Offers analytical and testing services to support pharmaceutical development and manufacturing.
Leadership and Structure
Franco Stevanato is the Executive Chairman. Franco Moro is the Chief Executive Officer. The company operates with a board of directors and a structured management team overseeing different business units.
Top Products and Market Share
Key Offerings
- Glass Vials: High-quality glass vials for injectable drugs. Competitors include Schott AG, Gerresheimer AG, and Corning Incorporated. Stevanato Group has a significant market share, estimated to be in the 20-25% range for high-value vials. Revenue contribution is significant, estimated at approximately 30-40% of total revenue.
- Syringes: Pre-fillable syringes for vaccines and other injectable drugs. Competitors are Becton Dickinson (BDX), SCHOTT, and Gerresheimer. Stevanato Group market share is around 15-20% globally. Contributing around 25-35% of total revenue.
- Cartridges: Glass and plastic cartridges for insulin pens and auto-injectors. Main competitors are SCHOTT, Becton Dickinson. Market share around 10-15%. Revenue accounts around 10-15% of the total revenue
- Inspection Machines: Automatic visual inspection machine for pharmaceutical containers. Main competitor is Antares Vision. Insignificant market share but potentially lucrative. Accounts for ~5% revenue of total revenue.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery market is driven by increasing demand for injectable drugs, biologics, and biosimilars. Regulatory requirements and the need for high-quality packaging are also key factors.
Positioning
Stevanato Group is positioned as a leading provider of high-value pharmaceutical packaging and equipment. Its competitive advantages include its integrated offering, global presence, and focus on innovation.
Total Addressable Market (TAM)
The global pharmaceutical packaging market is expected to reach over $150 billion by 2028. Stevanato Group is well-positioned to capture a significant share of this market due to its expertise in high-value packaging solutions.
Upturn SWOT Analysis
Strengths
- Strong global presence
- Integrated offering (packaging and equipment)
- Focus on innovation and technology
- Established relationships with major pharmaceutical companies
- High quality standards
Weaknesses
- Dependence on the pharmaceutical industry
- Exposure to raw material price fluctuations
- Competition from larger, more diversified companies
- Geographic concentration in Europe and North America
Opportunities
- Growing demand for injectable drugs and biologics
- Expansion into emerging markets
- Development of new packaging technologies
- Acquisition of complementary businesses
- Increasing adoption of ready-to-use drug delivery systems
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Technological obsolescence
- Counterfeit products
Competitors and Market Share
Key Competitors
- Becton, Dickinson and Company (BDX)
- Gerresheimer AG (GXI:GR)
- Schott AG (Private)
Competitive Landscape
Stevanato Group's advantages include its integrated offering, focus on innovation, and strong relationships with pharmaceutical companies. Disadvantages include its smaller size compared to some of its competitors and its geographic concentration.
Major Acquisitions
Balda AG
- Year: 2016
- Acquisition Price (USD millions): 134
- Strategic Rationale: Expanded capabilities in plastic molding for pharmaceutical applications.
Growth Trajectory and Initiatives
Historical Growth: Stevanato Group has experienced strong growth in recent years, driven by increasing demand for its products and services. This growth has been fueled by both organic expansion and strategic acquisitions.
Future Projections: Analyst estimates project continued revenue growth for Stevanato Group in the coming years, driven by the favorable industry trends and the company's competitive strengths. Growth is expected to be in the range of 8-12% per year.
Recent Initiatives: Recent initiatives include investments in new manufacturing capacity, expansion into emerging markets, and the development of innovative packaging solutions.
Summary
Stevanato Group is a strong player in the pharmaceutical packaging industry, benefiting from increasing demand for injectable drugs and biologics. The company's integrated offering and focus on innovation are working well, but it needs to diversify geographically and manage raw material price fluctuations carefully. Future growth depends on strategic investments and continued innovation. Maintaining a high standard for quality will ensure continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stevanato Group SpA
Exchange NYSE | Headquaters Piombino Dese, PD, Italy | ||
IPO Launch date 2021-07-16 | CEO & Executive Chairman Mr. Franco Stevanato | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 5521 | Website https://www.stevanatogroup.com |
Full time employees 5521 | Website https://www.stevanatogroup.com | ||
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.